Splco emerging trend in bilingual online media
Pharma Company Cipla Ltd is looking to make the generic version of US-based Gilead Sciences’ anti-viral drug remdesivir available in India in the next 8-10 days and price it less than ₹ 5,000 per vial Gilead Sciences extended a voluntary non-exclusive license to Cipla in May to manufacture and market Cipla’s generic version of remedisvir Read More…
Hyderabad-based Hetero will launch remdesivir, an injectable drug from Gilead, to treat hospitalised Covid-19 patients within this week. The company will first make the drug available in the main disease burden areas of Maharashtra and Delhi under the brand Covifor. A single dose vial is likely to cost between Rs 5,000-6000, the company said. Read More…
